Tourmaline Bio Inc
TRML
ISIN null / Valor 130396424
Tourmaline Bio Inc
UMushroom community rating:
About company
Tourmaline Bio Inc is a biotechnology firm focused on the development and commercialization of innovative therapies in the healthcare sector. Founded by Sandeep, who brings nearly two decades of experience in healthcare, biotech investment, and company development, Tourmaline aims to leverage its leadership's extensive background to advance its portfolio. Sandeep's prior roles include significant positions at KVP Capital, Immunovant, Roivant Sciences, and QVT Financial, highlighting a career deeply embedded in biotech company growth and public transactions. Alongside Sandeep, Gerhard, with over twenty years of experience in the biopharma industry, contributes his expertise in drug development, commercial strategy, and business development, having previously led significant initiatives and product launches at Gilead Sciences and Pfizer. Tourmaline Bio Inc's leadership is characterized by a rich history of strategic and operational success across various stages of drug development and commercialization, positioning the company to make impactful advances in the healthcare and biotech industries.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (04.10.2025):
Tourmaline Bio Inc reported its financial results for the third quarter of 2024, showcasing a substantial increase in cash reserves to $314.4 million while experiencing higher operating expenses and a net loss of $20.2 million. The company continues to advance its clinical trials, positioning itself for key data readouts in 2025.
Cash Position
As of September 30, 2024, Tourmaline Bio Inc holds $314.4 million in cash, cash equivalents, and investments, up from $203.0 million at the end of December 2023. This robust cash position is expected to support operations through 2027, covering key clinical trial milestones in TED and cardiovascular disease.
Operating Expenses
Research and development expenses surged to $19.3 million for Q3 2024 compared to $3.8 million in the same quarter of 2023, driven by higher employee compensation, increased drug manufacturing costs, and expanded clinical trial activities. General and administrative expenses also rose to $5.1 million from $2.9 million, primarily due to increased headcount, insurance costs, and professional service fees.
Net Loss
Net loss for the third quarter of 2024 was $20.2 million, up from $5.6 million in Q3 2023. The increase in net loss is attributed to higher operating expenses and company growth. However, the net loss per share decreased to $0.78 from $5.16, thanks to the issuance of additional shares through a reverse merger and subsequent public offerings.
Clinical Highlights and Upcoming Milestones
Tourmaline Bio Inc continues to make progress in its clinical programs, including the ongoing Phase 2 TRANQUILITY trial with expected topline data in the first half of 2025. The pivotal spiriTED Phase 2b trial in TED is also on track, with topline results anticipated in the second half of 2025 and plans to initiate a Phase 3 trial in late 2024.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
1233 M
Market cap (USD)
Daily traded volume (Shares)
20.46 / 19.68
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
